Original Article

You have full text access to this OnlineOpen article

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia†‡

A Study From the Acute Leukemia French Association

  1. Aline Renneville MD1,2,3,§,
  2. Nicolas Boissel MD, PhD4,5,§,
  3. Virginie Zurawski MD1,2,3,
  4. Laura Llopis MD1,2,3,
  5. Valéria Biggio PhD1,2,3,
  6. Olivier Nibourel MD1,2,3,
  7. Nathalie Philippe PhD1,2,3,
  8. Xavier Thomas MD6,
  9. Hervé Dombret MD4,5,
  10. Claude Preudhomme MD, PhD1,2,3,¶,*

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24442

Issue

Cancer

Cancer

Volume 115, Issue 16, pages 3719–3727, 15 August 2009

Additional Information

How to Cite

Renneville, A., Boissel, N., Zurawski, V., Llopis, L., Biggio, V., Nibourel, O., Philippe, N., Thomas, X., Dombret, H. and Preudhomme, C. (2009), Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia. Cancer, 115: 3719–3727. doi: 10.1002/cncr.24442

Author Information

  1. 1

    Department of Hematology, Biology and Pathology Center, University of Lille Medical School, Lille, France

  2. 2

    Cancer Research Institute, J. P. Aubert Center, Inserm U-837, Team 3, Lille, France

  3. 3

    Onco-Hematology Axis, Northwest Canceropole, Lille, France

  4. 4

    EA 3518, University of Paris, Paris, France

  5. 5

    Department of Adult Hematology, St. Louis Hospital, Paris, France

  6. 6

    Department of Hematology, Edouard Herriot Hospital, Lyon, France

  1. §

    The two first authors contributed equally to this article.

  2. Fax: (011) 333-20-44-6989

*Department of Hematology, Biology and Pathology Center, Professor Leclercq Boulevard, 59037 Lille Cedex, France

  1. †

    We thank all patients and members of the Acute Leukemia French Association for their participation.

  2. ‡

    The following additional members of the Acute Leukemia French Association (ALFA) contributed to this work: Sandrine Hayette, MD (Department of Cytogenetics and Molecular Biology, Edouard Herriot Hospital, Lyon, France) Stéphane de Botton, MD, PhD (Gustave Roussy Institute, Villejuif, France) Jean-Michel Cayuela, MD, PhD (Department of Hematology, St. Louis Hospital, Paris, France) Dominique Bories, MD (Department of Hematology, Henri Mondor Hospital, Créteil, France); Xavier Troussard, MD (Department of Hematology, Caen Hospital, Caen, France); Christine Terré, MD (Department of Cytogenetics, André Mignot Hospital, Versailles, France); and Sylvie Castaigne, MD (Department of Hematology and Oncology, André Mignot Hospital, Versailles, France).

Publication History

  1. Issue published online: 3 AUG 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 22 JAN 2009
  4. Manuscript Revised: 19 JAN 2009
  5. Manuscript Received: 4 SEP 2008

Funded by

  • Fondation de France (Leukemia Committee)
  • North-West Canceropole (Onco-Hematology Axis)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (177K)

References

  • 1
    Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999; 93: 3074-3080.
  • 2
    Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998; 58: 55-59.
  • 3
    Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002; 100: 2717-2723.
  • 4
    Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005; 106: 3740-3746.
  • 5
    Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106: 3733-3739.
  • 6
    Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005; 106: 3747-3754.
  • 7
    Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008; 22: 915-931.
  • 8
    Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-1918.
  • 9
    Keilholz U, Menssen HD, Gaiger A, et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia. 2005; 19: 1318-1323.
  • 10
    Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007; 21: 868-876.
  • 11
    Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat. 1997; 9: 209-225.
    Direct Link:
  • 12
    Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996; 87: 2878-2884.
  • 13
    Svedberg H, Chylicki K, Baldetorp B, Rauscher FJ 3rd, Gullberg U. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene. 1998; 16: 925-932.
  • 14
    Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001; 20: 1897-1909.
  • 15
    Nishida S, Hosen N, Shirakata T, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2006; 107: 3303-3312.
  • 16
    Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007; 14: 1-17.
  • 17
    Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica. 2004; 89: 926-933.
  • 18
    Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol. 2004; 125: 590-600.
    Direct Link:
  • 19
    Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006; 24: 1507-1515.
  • 20
    Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008; 93: 921-924.
  • 21
    King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood. 1996; 87: 2171-2179.
  • 22
    King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998; 91: 2961-2968.
  • 23
    Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya K. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer. 1999; 25: 176-183.
    Direct Link:
  • 24
    Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007; 21: 550-551.
  • 25
    Paschka P, Marcucci Ruppert AS, et al. Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008; 26: 4595-4602.
  • 26
    Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008; 26: 5429-5435.
  • 27
    Thomas X, Raffoux E, de Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007; 21: 453-461.
  • 28
    MittelmannF, ed. Guidelines for Cancer Cytogenetics. Supplement to An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
  • 29
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333.
  • 30
    Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997; 11: 1447-1452.
  • 31
    Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001; 97: 2434-2439.
  • 32
    Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005; 106: 3618-3620.
  • 33
    Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990; 8: 813-819.
View Full Article (HTML) Get PDF (177K)